Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach
Liver cancer, particularly hepatocellular carcinoma (HCC), represents a significant global health burden with limited treatment options and poor prognosis. This article provides a comprehensive overview of pharmacotherapy for liver cancer, focusing on both established and emerging drugs. Curren...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Krupanidhi College of Pharmacy
2024-11-01
|
| Series: | Journal of Pharmaceutical Research |
| Online Access: | https://jopcr.com/articles/combining-multi-kinase-inhibitors-and-immune-checkpoints-blockade-in-hepatocellular-carcinoma-a-pharmacotherapeutic-approach |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849230151018086400 |
|---|---|
| author | Vothani Sarath Babu P Bhavana Sree C Pallavi S Pavithra P M Vasanth |
| author_facet | Vothani Sarath Babu P Bhavana Sree C Pallavi S Pavithra P M Vasanth |
| author_sort | Vothani Sarath Babu |
| collection | DOAJ |
| description |
Liver cancer, particularly hepatocellular carcinoma (HCC), represents a significant global health burden with limited treatment options and poor prognosis. This article provides a comprehensive overview of pharmacotherapy for liver cancer, focusing on both established and emerging drugs. Current standard-of-care treatments, including sorafenib and lenvatinib, target key pathways involved in tumor growth and angiogenesis. However, their efficacy is often limited, prompting ongoing research into novel therapeutic approaches. Emerging immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, have shown promise in clinical trials, offering new avenues for personalized treatment strategies. Additionally, targeted therapies aimed at specific genetic alterations, such as FGFR inhibitors for FGFR-altered HCC, demonstrate potential for improved outcomes in select patient populations. These abstract highlights the evolving landscape of pharmacotherapy for liver cancer and underscores the need for further research to optimize treatment efficacy and patient outcomes.
Keywords
Multikinase Inhibitors, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC), Sorafenib |
| format | Article |
| id | doaj-art-4a45861427de43d18e287e7b58e58a57 |
| institution | Kabale University |
| issn | 0973-7200 2454-8405 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Krupanidhi College of Pharmacy |
| record_format | Article |
| series | Journal of Pharmaceutical Research |
| spelling | doaj-art-4a45861427de43d18e287e7b58e58a572025-08-21T09:34:09ZengKrupanidhi College of PharmacyJournal of Pharmaceutical Research0973-72002454-84052024-11-0123314114710.18579/jopcr/v23.3.75Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic ApproachVothani Sarath BabuP Bhavana SreeC PallaviS PavithraP M Vasanth Liver cancer, particularly hepatocellular carcinoma (HCC), represents a significant global health burden with limited treatment options and poor prognosis. This article provides a comprehensive overview of pharmacotherapy for liver cancer, focusing on both established and emerging drugs. Current standard-of-care treatments, including sorafenib and lenvatinib, target key pathways involved in tumor growth and angiogenesis. However, their efficacy is often limited, prompting ongoing research into novel therapeutic approaches. Emerging immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, have shown promise in clinical trials, offering new avenues for personalized treatment strategies. Additionally, targeted therapies aimed at specific genetic alterations, such as FGFR inhibitors for FGFR-altered HCC, demonstrate potential for improved outcomes in select patient populations. These abstract highlights the evolving landscape of pharmacotherapy for liver cancer and underscores the need for further research to optimize treatment efficacy and patient outcomes. Keywords Multikinase Inhibitors, Immune Checkpoint Inhibitors, Hepatocellular Carcinoma (HCC), Sorafenibhttps://jopcr.com/articles/combining-multi-kinase-inhibitors-and-immune-checkpoints-blockade-in-hepatocellular-carcinoma-a-pharmacotherapeutic-approach |
| spellingShingle | Vothani Sarath Babu P Bhavana Sree C Pallavi S Pavithra P M Vasanth Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach Journal of Pharmaceutical Research |
| title | Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach |
| title_full | Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach |
| title_fullStr | Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach |
| title_full_unstemmed | Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach |
| title_short | Combining Multi-kinase Inhibitors and Immune Checkpoints Blockade in Hepatocellular Carcinoma: A Pharmacotherapeutic Approach |
| title_sort | combining multi kinase inhibitors and immune checkpoints blockade in hepatocellular carcinoma a pharmacotherapeutic approach |
| url | https://jopcr.com/articles/combining-multi-kinase-inhibitors-and-immune-checkpoints-blockade-in-hepatocellular-carcinoma-a-pharmacotherapeutic-approach |
| work_keys_str_mv | AT vothanisarathbabu combiningmultikinaseinhibitorsandimmunecheckpointsblockadeinhepatocellularcarcinomaapharmacotherapeuticapproach AT pbhavanasree combiningmultikinaseinhibitorsandimmunecheckpointsblockadeinhepatocellularcarcinomaapharmacotherapeuticapproach AT cpallavi combiningmultikinaseinhibitorsandimmunecheckpointsblockadeinhepatocellularcarcinomaapharmacotherapeuticapproach AT spavithra combiningmultikinaseinhibitorsandimmunecheckpointsblockadeinhepatocellularcarcinomaapharmacotherapeuticapproach AT pmvasanth combiningmultikinaseinhibitorsandimmunecheckpointsblockadeinhepatocellularcarcinomaapharmacotherapeuticapproach |